目的：探讨头孢哌酮钠舒巴坦钠的不同给药途径对治疗腹膜透析相关性腹膜炎的临床效果.方法本项研究选择接受腹膜透析相关性腹膜炎治疗的60例患者作为研究对象,将入组患者随机分为两组,即观察组与对照组.观察组患者通过腹膜透析通路给药,将头孢哌酮钠舒巴坦钠1.5 g加入1.5%腹透液2000 mL中,留腹过夜,疗程为2周,2次/d.对照组患者通过静脉给药,给予0.9%生理盐水100 mL+头孢哌酮钠舒巴坦钠1.5 g静脉滴注,疗程为2周,2次/d.结果观察组有15例(50.0%)患者痊愈,对照组有10例(33.3%)患者痊愈,两组比较差异具有统计学意义.结论在使用头孢哌酮钠舒巴坦钠进行腹膜透析相关性腹膜炎治疗过程中,通过腹膜透析通路给药途径治疗效果理想,值得临床推广使用.%Objective To explore the effects of Cefoperazone Sodium and Sulbactam Sodium administrated in different routes on the treatment of peritoneal dialysis associated peritonitis (PDAP). Method 60 patients who underwent PDAP treatment were selected as the research object. In order to achieve the therapeutic effect, Cefoperazone Sodium and Sulbactam Sodium were delivered in different ways. The patients were randomly divided into the observation group and the control group. In the observation group,Cefoperazone Sodium and Sulbactam Sodium was delivered through the pertioneal dialysis access. An amount of 1. 5 g drug was added into 2 000 mL of 1. 5% peritoneal dialysis fluid,kept in abdomen over the night,2 times per day for 2 weeks. The control group was administrated 1. 5 g drug in 100 mL of 0. 9% saline by intravenous drip,2 times per day or 2 weeks. Results In the observation group,15 patients were cured,accounting for 50. 0%,and the recovery rate of the control group was 33. 3%. Comparison between the two groups showed statistically significant difference. Conclusion In the process of treating Cefoperazone Sodium and Sulbactam Sodium for PDAP,the administration through peritoneal dialysis access is worth for clinic application and promotion.
展开▼
